Centre Hospitalier Metropole Savoie — Clinical Trial Site

57 Registered trials

25 Currently recruiting

Organisation

Centre Hospitalier Metropole Savoie

Location

Chambery, France

Identifier

ORG-100041758

Address

Place Lucien Biset, Bp 31125, 73000, France

Departments

-
2202: Cardiology
Cardiologie
Department of Nephrology and Dialysis
gastroenterology
Hématologie
Hématologie Oncologie
Hematology
Hematology Department
Hepato-gastroenterology and oncology
INFECTIOLOGIE
Infectious diseas
Maladies Infectieuses
médecine nucléaire
medecine nuclear department
Medical and Surgical ICU
Medical Oncology
Néonatologie et réanimation néonatale
Neonatology
Obstetrics
Oncologie
Oncologie médicale
oncology
Pneumologie
Pneumology
Radiotherapy
Réanimation Médico-Chirurgicale
Santé Mentale et justice
Service d'hématologie
Service d’hématologie
Service de Cardiologie
Service de Pneumologie
Service Hématologie

Clinical trials at this site (57)

Search interface

MInimal residual Disease Adapted Strategy / IFM 2020-02 Pending

2024-513889-19-00 Multiple Myeloma 5
Rifampin-free regimen versus rifampin-containing regimen in the treatment of staphylococcal prosthetic valve endocarditis: a multicenter ran… Pending

2024-518018-22-00 staphylococcal endocarditis 5
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy with Standard-of-Care Combination Regimens … Pending

2024-519504-27-00 Relapsed Refractory Multiple Myeloma 5
Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Pending

2024-519655-28-00 Premenopausal patients with high-risk HR-positive/HER2- 5
Study PACIFIC: Fixed duration treatment with combined pirtobrutinib and short course immuno-chemotherapy in fit patients with previously unt… Pending

2025-521199-80-00 Patients with previously untreated symptomatic chronic 4
Etude de phase II évaluant la capacité d'un agoniste des récepteurs 5-HT4, le prucalopride (Resolor©), à accélérer l'efficacité thérapeutiqu… Pending

2025-521811-38-01 Dépression 4
NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting

2025-520979-13-00 Patients with HR+ HER2- early breast cancer at intermed 5 2025-12-18
Study assessing the efficacy of etoposide free chemotherapy plus durvalumab in first line extensive disease Small Cell Lung Cancer Recruiting

2023-504670-38-00 Extensive disease Small Cell Lung Cancer 4 2023-11-17
AMUNDSEN - Acute Myocardial infarction Upbound to percutaneous coronary intervention, immediately (STEMI) or in the Next three Days (NSTEMI)… Recruiting

2024-518195-31-00 acute myocardial infarction 6 2021-09-29
A multi-center phase III randomized study comparing continuous versus fixed duration therapy with Daratumumab, Lenalidomide, and Dexamethaso… Recruiting

2024-511855-16-00 Onco-hematology 5 2019-07-25
PIPELINE-RSV-France Recruiting

2025-521755-23-00 Respiratory syncytial virus infection 5 2026-04-28
A clinical study of MK-1084 and other treatments for lung cancer (MK-1084-007) Recruiting

2024-514500-14-00 Participants with KRAS G12C-Mutant, Advanced or Metasta 5 2025-12-15
Immunogenicity and safety of the 20-Valent pneumococcal conjugate vaccine (PCV-20) administered during an acute febrile illness in adults Recruiting

2024-517411-73-00 Patient with medium or high risk for pneumococcal invas 6 2025-11-12
Efficacy of dexmedetomidine versus midazolam sedation on extubation time in mechanically ventilated preterm infants: a randomized controlled… Recruiting

2023-508785-16-00 Very preterm neonate (gestational age at birth < 32 WG) 5 2025-10-17
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-line Treatment of PD-L1-high Metastatic Non-small Cell Lung… Recruiting

2024-517780-24-00 Lung Cancer 5 2025-09-18
A phase 3, open-label, controlled, randomized study of newly diagnosed multiple myeloma treatment, designed to evaluate the efficacy and saf… Recruiting

2024-516418-39-00 Multiple Myeloma 5 2025-07-09
Free regimen of Dexamethasone as initial therapy for advanced relapsed/refractory multiple myeloma: an open-label randomized, non-inferiorit… Recruiting

2024-510981-18-00 Multiple Myeloma Multiple myeloma (MM) is a B cell mali 5 2024-12-12
FIRST LINE CHEMOTHERAPY FOR METASTATIC GASTRO ENTERO PANCREATIC NEUROENDOCRINE CARCINOMA Recruiting

2024-515300-39-00 METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE 4 2024-10-18
ARGO Colchicine versus Placebo in Acute Myocarditis Patients to Reduce Late Gadolinium Enhancement Mass on Cardiac Magnetic Resonance and th… Recruiting

2024-514610-13-00 patients suffering from acute myocarditis confirmed on 5 2024-10-04
OPEN-LABEL PHASE II EFFICACY STUDY OF REPOTRECTINIB IN FRAIL (PS ≥2) AND /OR ELDERLYPATIENTS WITH ROS1-REARRANGED ADVANCED NSCLC Recruiting

2023-509073-23-00 Stage III/IV non-small-cell lung cancer (NSCLC) harbori 4 2024-10-01
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a… Recruiting

2023-505436-35-00 Untreated FLIPI 2-5 Follicular Lymphoma 5 2024-06-03
CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA Recruiting

2023-503317-29-00 Metastatic renal cell carcinoma (mRCC) 5 2024-04-12
A trial to learn if odronextamab combined with lenalidomide is safe and works better than rituximab combined with lenalidomide in adult part… Recruiting

2022-503092-28-00 Relapsed/Refractory Follicular Lymphoma 5 2024-01-08